Investigational drug · Phase 3
HPP2003-3
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertension.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "HPP2003-3"
First trial start
2024
Mar 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HPP2003-3", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HPP2003-3" as an intervention, largest first.
- A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential HypertensionPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT05362110 · 361 participants · Start May 16, 2022 · Primary completion Jun 5, 2023
Drug: HCP1803-3; RLD2002 and 2 more · For: Hypertension
Sites: Goyang-si, South Korea
- A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential HypertensionPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT06438172 · 249 participants · Start Mar 25, 2024 · Primary completion Dec 2, 2024
Drug: HCP1803-3; RLD2001-1 and 2 more · For: Hypertension
Sites: Goyang-si, South Korea
- A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential HypertensionPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT04959305 · 245 participants · Start Apr 22, 2021 · Primary completion Feb 28, 2022
Drug: HCP1803-3; RLD2003 and 4 more · For: Hypertension
Sites: Goyang-si, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypertension
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VCT220CX11Phase 35 trials
Vincentage Pharma Co., Ltd · Obesity, Type 2 Diabetes Mellitus (DM), Hypertension
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- ZilebesiranALN-AGT01Phase 34 trials
Alnylam Pharmaceuticals · Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.